



(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
21.11.2001 Bulletin 2001/47

(51) Int Cl.7: **A61L 24/02**

(21) Application number: **00110376.1**

(22) Date of filing: **15.05.2000**

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(71) Applicants:
• Lin, Chih-I
Chino Hills, CA 91709 (US)
• Lin, Shengfu
Taipei (TW)

(72) Inventors:
• Lin, Chih-I
Chino Hills, CA 91709 (US)
• Lin, Shengfu
Taipei (TW)

(74) Representative: **Grünecker, Kinkeldey,**
Stockmair & Schwanhäusser Anwaltssozietät
Maximilianstrasse 58
80538 München (DE)

(54) **Orthopedic filling material and method of use thereof**

(57) A method of using a plaster of Paris as an orthopedic filling material prepared by mixing 15-80% by weight of calcium sulfate halfhydrate and 85-20% by weight of water, an aqueous solution, an aqueous dispersion, or an aqueous suspension; and stirring the re-

sulting mixture into a paste having a viscosity in the range of 20 and 75 poises. The paste is injected into a cavity of a bone or a vertebra to be reinforced. The injected paste becomes hard in the cavity within a few minutes, and eventually will be absorbed by the patient.

Description

FIELD OF THE INVENTION

5 [0001] The present invention relates generally to an orthopedic filling material, and more particularly to an orthopedic filling material prepared from plaster of Paris having a specific viscosity, and the method of use of the orthopedic filling material.

BACKGROUND OF THE INVENTION

10 [0002] The bone cement is one of the important orthopedic filling materials and is used for filling the bone marrow gap in the orthopedic surgery, and the gap between the bone and the implant, thereby enabling the bone to have an appropriate strength after the surgery, or enabling the implant to be joined intimately with the bone. However, the bone cement is incapable of being absorbed by a human body and is apt to affect the blood-making function of the marrow.

15 [0003] The bone graft is another one of the important orthopedic filling materials. The advantage of the bone graft is that it is capable of promoting the bone ingrowth. However, the bone graft must be accompanied with an implant in view of the fact that the bone graft is incapable of bearing the burden of the pressure of the body weight of a patient prior to its fusion with the bone.

20 [0004] The synthetic orthopedic granule is also one of the important orthopedic filling materials; nevertheless, it shares with the bone graft the same drawback described above.

SUMMARY OF THE INVENTION

25 [0005] An objective of the present invention is to provide a calcium sulfate-containing orthopedic filling material having a specific viscosity.

[0006] Another objective of the present invention is to provide a method of using a plaster of Paris as an orthopedic filling material for the treatment of a deformed born in a patient, wherein said plaster of Paris is a paste having a viscosity ranging from 20 to 75 poises, and preferably, ranging from 30 to 60 poises.

DETAILED DESCRIPTION OF THE INVENTION

[0007] An orthopedic filling material made of plaster of Paris is disclosed in the present invention, which is a paste having a viscosity ranging from 20 to 75 poises, and preferably, ranging from 30 to 60 poises.

35 [0008] A suitable process for preparing the paste of the present invention comprises mixing 15-80%, preferably 20-75%, and more preferably 30-60%, by weight of calcium sulfate half-hydrate ($\text{CaSO}_4 \cdot 0.5\text{H}_2\text{O}$) and 85-20% by weight of water, an aqueous solution, an aqueous dispersion, or an aqueous suspension; stirring the resulting mixture into a paste. The resulting paste was rested for a period of time to have a desired viscosity.

[0009] A treatment of a deformed born according to the present invention comprises injecting said paste into a cavity of a born or a vertebra, which require treatment, as an orthopedic filling material, so that the injected paste will become hard in said cavity, and eventually will be absorbed by the patient.

40 [0010] Preferably, said paste of the present invention comprises 15-80%, more preferably 20-75%, and most preferably 30-60% by weight of calcium sulfate; and water, an aqueous solution, an aqueous dispersion, or an aqueous suspension as the balance.

[0011] The water used in the present invention can be distilled water, reverse-osmosis water, or pure water produced by other means.

45 [0012] The aqueous solution used in the present invention may contain certain remedial drugs (such as antibiotics, and bone ingrowth drugs), nutrients, or other additives.

[0013] The aqueous dispersion used in the present invention may contain remedial drugs (such as antibiotics, and bone ingrowth drugs), nutrients, or other additives, which are dispersed in water with a dispersing agent.

50 [0014] The aqueous suspension used in the present invention may contain remedial drugs (such as antibiotics, and bone ingrowth drugs), nutrients, or other additives.

[0015] In the process for preparing the paste of the present invention, drugs or nutrients may be added before the mixing or in the midst of the mixing such that they are mixed with the calcium sulfate half-hydrate and water, the aqueous solution, the aqueous dispersion or the aqueous suspension.

55 [0016] The drugs, nutrients, and additives may be in the form of solid, liquid, or gas. The drugs and nutrients added should not have adverse effect on the hardening of the paste. The additives can have a direct effect or an indirect effect on the paste, such as hardening promoters, hardening delaying agents, and the like.

[0017] The paste of the present invention has a viscosity ranging between 20 and 75 poises, preferably between 30

EP 1 155 704 A1

and 60 poises. If the viscosity of the paste is too low, the paste is apt to disperse quickly into the body fluid before the paste solidifies in the cavity of the bone or vertebra. If the viscosity of the paste is excessively high, the paste can not be easily injected into the cavity of the bone or vertebra.

[0018] The chemical formula of the calcium sulfate half-hydrate used in preparing the paste of the present invention consists essentially of $\text{CaSO}_4 \cdot 0.5\text{H}_2\text{O}$. The chemical formula of the calcium sulfate of the paste of the present invention is a mixture of $\text{CaSO}_4 \cdot n\text{H}_2\text{O}$, in which n has a value of 0, 0.5, 2, or others.

[0019] The viscosity of the paste of the present invention is measured by a RVS-1 Rotary viscometer available from Fargo Company, Taipei, Taiwan.

Examples 1-12 :

[0020] A paste was formed by mixing at 30rpm for one minute at 27°C 10 grams of the half-water calcium sulfate and 3.6 ml of pure water. The paste was rested without disturbance. 5 ml of paste was then taken out with an injector having an injection outlet inner diameter of 0.8 mm at different take-out time, and immediately injected on a bottom of a beaker containing 100 ml saline water. Thereafter, the hardening of the injected paste in the saline water was observed 20 minutes after injection. The results are shown in Table 1.

Table 1

Example	Take-out time (min)	Viscosity (poise)	Hardening State ^{a)}	Take-out/Injection Condition ^{b)}
1	2	14	×	+
2	3	20	Δ	+
3	4	28	ΔΔ	+
4	5	30	○	+
5	8	31	○	+
6	10	32	○	+
7	11	48	○	+
8	12	55	○	+
9	13	58	○	+
10	14	67	○	-
11	15	70	○	-
12	16	80	○	--

a) ×: no hardening, the injected paste disperses

Δ: the injected paste becomes flat and hard

ΔΔ: the bottom of the injected paste becomes bigger and hard

○: the injected paste become hard with substantially no change in shape

b) + : take-out and injection without problem

- : Injection being slightly difficult

--: Injection being extremely difficult

Examples 13-20:

[0021] These examples were similar to Examples 1-12, except that the agitation time was changed to 30 seconds, and that the temperature was changed to 30°C. The results are shown in Table 2.

Table 2

Example	Take-out Time (min)	Viscosity (poise)	Hardening State ^{a)}	Take-out/Injection Condition ^{b)}
13	4	27	ΔΔ	+
14	5	30	○	+
15	6	31	○	+

a), b) defined as in Table 1

EP 1 155 704 A1

Table 2 (continued)

Example	Take-out Time (min)	Viscosity (poise)	Hardening State ^{a)}	Take-out/Injection Condition ^{b)}
16	7	42	○	+
17	8	56	○	+
18	9	72	○	-
19	10	80	○	--
20	11	82	○	--

a), b) defined as in Table 1

Examples 21-27:

[0022] These examples were similar to Examples 1-12, except that the agitation time was 10 seconds, and that the temperature was 30°C, and further that 0.9wt% of sodium chloride solution was used in place of pure water. The results are shown in Table 3.

Table 3

Example	Take-out Time (min)	Viscosity (poise)	Hardening State ^{a)}	Take-out/Injection Condition ^{b)}
21	10	20	Δ	+
22	20	30	○	+
23	50	52	○	+
24	80	44	○	+
25	100	56	○	+
26	120	78	○	--
27	140	180	-	Could not be taken out

a), b) defined as in Table 1

Examples 28-32:

[0023] 9.5 grams of calcium sulfate half-hydrate and 0.5 gram of hydroxyapatite (HA) were mixed with 3.6 ml of pure water at 29°C and were agitated for 20 seconds. The paste was rested without disturbance. 5 ml of paste was then taken out with an injector having an injection outlet inner diameter of 0.8 mm at different take-out time, and immediately injected on a bottom of a beaker containing 100 ml saline water. Thereafter, the hardening of the injected paste in the saline water was observed. The results are shown in Table 4.

Table 4

Example	Take-out Time (min)	Viscosity (poise)	Hardening State ^{a)}	Take-out/Injection Condition ^{b)}
28	30	40	○	+
29	50	52	○	+
30	100	60	○	+
31	120	75	○	-
32	150	90	○	--

a), b) defined as in Table 1

Examples 33-40:

[0024] These examples were similar to Examples 28-32, except that the amount of pure water was increased to 4.8 ml. The results are shown in Table 5.

EP 1 155 704 A1

Table 5

Example	Take-out Time (sec)	Viscosity (poise)	Hardening State ^{a)}	Take-out/Injection Condition ^{b)}
33	200	17	×	+
34	210	19	Δ	+
35	220	25	ΔΔ	+
36	230	28	ΔΔ	+
37	240	33	○	+
38	300	42	○	+
39	330	58	○	+
40	340	77	○	--

a), b) defined as in Table 1

Examples 41-18:

[0025] These examples were similar to Examples 28-32, except that the amount of pure water was increased to 6 ml. The results are shown in Table 6.

Table 6

Example	Take-out Time (sec)	Viscosity (poise)	Hardening State ^{a)}	Take-out/Injection Condition ^{b)}
41	300	20	×	+
42	320	21	Δ	+
43	350	28	ΔΔ	+
44	400	29	ΔΔ	+
45	420	32	○	+
46	450	53	○	+
47	480	64	○	-
48	550	85	○	--

a), b) defined as in Table 1

Examples 49-50:

[0026] These examples were similar to Examples 1-12, except that an aqueous suspension containing 0.5% by weight of calcium sulfate dihydrate was used in place of the pure water. The results are shown in Table 7.

Table 7

Example	Take-out Time (sec)	Viscosity (poise)	Hardening State ^{a)}	Take-out/Injection Condition ^{b)}
49	30	35	○	+
50	60	48	○	+

a), b) defined as in Table 1

Claims

1. Use of a plaster of Paris in the manufacture of an orthopedic filling material for the treatment of a deformed bone in a patient, wherein said plaster of Paris is a paste having a viscosity ranging from 20 to 75 poises.
2. The use as defined in claim 1, wherein said paste has a viscosity ranging between 30 and 60 poises.

EP 1 155 704 A1

3. The use as defined in claim 1, wherein the treatment of a deformed born comprising injecting said paste into a cavity of a born or a vertebra, which require treatment, as an orthopedic filling material, so that the injected paste will become hard in said cavity, and eventually will be absorbed by the patient.

5 4. The use as defined in claim 1, wherein said paste comprises 15-80% by weight of calcium sulfate; and water, an aqueous solution, an aqueous dispersion, or an aqueous suspension as the balance.

5. The use as defined in claim 4, wherein said paste contains 20-75% by weight of calcium sulfate.

10 6. The use as defined in claim 5, wherein said paste contains 30-60% by weight of calcium sulfate.

7. The use as defined in claim 1, wherein said paste is prepared by mixing 15-80% by weight of calcium sulfate half-hydrate ($\text{CaSO}_4 \cdot 0.5\text{H}_2\text{O}$) and 85-20% by weight of water, an aqueous solution, an aqueous dispersion, or an aqueous suspension; and stirring the resulting mixture into a paste.

15

8. The use as defined in claim 7, wherein 20-75% by weight of calcium sulfate half-hydrate is mixed.

9. The use as defined in claim 8, wherein 30-60% by weight of calcium sulfate half-hydrate is mixed.

20

25

30

35

40

45

50

55



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 00 11 0376

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	SATO SHIGERU ET AL.: "Osteogenic response of rabbit tibia to hydroxyapatite particle-Plaster of Paris mixture" BIOMATERIALS, vol. 19, no. 20, 1 October 1998 (1998-10-01), pages 1895-1900, XP002149657 * abstract * * page 1896, left-hand column, paragraph 2 - page 1896, right-hand column, paragraph 2; figure 1 *	1-9	A61L24/02
X	US 4 619 655 A (AMBROSE WALLACE W ET AL) 28 October 1986 (1986-10-28) * the whole document *	1-9	
X	TAY BOBBY K B ET AL: "Calcium sulfate- and calcium phosphate-based bone substitutes." ORTHOPEDIC CLINICS OF NORTH AMERICA, vol. 30, no. 4, October 1999 (1999-10), pages 615-623, XP000951628 ISSN: 0030-5898 * page 616, left-hand column, paragraph 3 - page 616, right-hand column, paragraph 3 * * page 618, left-hand column, paragraph 2 - right-hand column, paragraph 3 *	1-9	
X	PELTIER LEONARD F ET AL.: "The use of Plaster of Paris to fill large defects in bone" AMERICAN JOURNAL OF SURGERY, vol. 97, 1959, XP000951629 * page 312, left-hand column, paragraph 1 - page 315, left-hand column, paragraph 2 *	1-9	
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 10 October 2000	Examiner Heck, G
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 (03/02) (P4/C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 11 0376

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

10-10-2000

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4619655 A	28-10-1986	CA 1241030 A	23-08-1988

EPO FORM P459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82